JP2004505898A5 - - Google Patents

Download PDF

Info

Publication number
JP2004505898A5
JP2004505898A5 JP2002517004A JP2002517004A JP2004505898A5 JP 2004505898 A5 JP2004505898 A5 JP 2004505898A5 JP 2002517004 A JP2002517004 A JP 2002517004A JP 2002517004 A JP2002517004 A JP 2002517004A JP 2004505898 A5 JP2004505898 A5 JP 2004505898A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
phosphate
compound
meg
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002517004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505898A (ja
Filing date
Publication date
Priority claimed from IL13767200A external-priority patent/IL137672A0/xx
Application filed filed Critical
Publication of JP2004505898A publication Critical patent/JP2004505898A/ja
Publication of JP2004505898A5 publication Critical patent/JP2004505898A5/ja
Pending legal-status Critical Current

Links

JP2002517004A 2000-08-03 2001-08-01 分岐鎖状親油性分子の誘導体及びそれらの使用 Pending JP2004505898A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13767200A IL137672A0 (en) 2000-08-03 2000-08-03 Derivatives of branched-chain lipophilic molecules and uses thereof
PCT/IL2001/000713 WO2002011666A2 (en) 2000-08-03 2001-08-01 Derivatives of branched-chain lipophilic molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2004505898A JP2004505898A (ja) 2004-02-26
JP2004505898A5 true JP2004505898A5 (cg-RX-API-DMAC7.html) 2008-08-14

Family

ID=11074480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002517004A Pending JP2004505898A (ja) 2000-08-03 2001-08-01 分岐鎖状親油性分子の誘導体及びそれらの使用

Country Status (16)

Country Link
US (2) US7186703B2 (cg-RX-API-DMAC7.html)
EP (1) EP1305322B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004505898A (cg-RX-API-DMAC7.html)
KR (1) KR100801207B1 (cg-RX-API-DMAC7.html)
CN (1) CN100467476C (cg-RX-API-DMAC7.html)
AT (1) ATE455120T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001280043B2 (cg-RX-API-DMAC7.html)
BR (1) BR0112835A (cg-RX-API-DMAC7.html)
CA (1) CA2416808C (cg-RX-API-DMAC7.html)
CZ (1) CZ2003208A3 (cg-RX-API-DMAC7.html)
DE (1) DE60141074D1 (cg-RX-API-DMAC7.html)
ES (1) ES2338987T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0301711A3 (cg-RX-API-DMAC7.html)
IL (1) IL137672A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ523664A (cg-RX-API-DMAC7.html)
WO (1) WO2002011666A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
AU2002224354A1 (en) 2000-10-10 2002-04-22 University Of North Carolina At Chapel Hill Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers
EP1485107A1 (en) 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
US20050222061A1 (en) 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
AU2006249347A1 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2009023631A1 (en) * 2007-08-10 2009-02-19 Basil Rigas Anti-inflammatory compounds and uses thereof
JP2011513318A (ja) * 2008-02-28 2011-04-28 ヘンリ フオルド ヘルス システム 中枢神経系損傷の治療を強化するために間質細胞を使用する組成物及び方法
WO2010107487A2 (en) * 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
JP5853869B2 (ja) * 2012-06-07 2016-02-09 日油株式会社 ホスホリルコリン基含有化合物及びその製造法
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3006946A (en) * 1953-03-04 1961-10-31 Union Carbide Corp Production of heterocyclic phosphoruscontaining compounds and products
US3260688A (en) 1962-08-10 1966-07-12 Toyo Koatsu Ind Inc Resin compositions for producing cellular masses and process for producing a cellular product
US3260668A (en) * 1964-11-04 1966-07-12 Dow Chemical Co Alkaline scale control in saline water conversion equipment
DE2038829C3 (de) * 1970-08-05 1975-11-13 Chemische Werke Huels Ag, 4370 Marl Zusatzmittel zu Mörtel oder Beton auf Zementbasis
LU65735A1 (cg-RX-API-DMAC7.html) 1972-07-17 1974-01-28
DE2930756A1 (de) 1979-07-28 1981-02-26 Cassella Ag Klotzhilfsmittel und verfahren zum faerben von cellulosefasern bzw. gemischen von cellulosefasern zusammen mit synthesefasern mit schwefel-, schwefelkuepen-, kuepen- und reaktivfarbstoffen
JPS6038363B2 (ja) 1979-11-27 1985-08-31 ライオン株式会社 ヘアリンス剤
JPS5716064A (en) * 1980-07-04 1982-01-27 Dai Ichi Kogyo Seiyaku Co Ltd Dye dispersion
JPS57112317A (en) * 1980-12-29 1982-07-13 Lion Corp Hairdressing agent composition
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
JPS6072829A (ja) 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
JPS60184092A (ja) 1984-03-01 1985-09-19 Kao Corp リン酸エステルおよびその製法
JPH0832832B2 (ja) * 1984-03-09 1996-03-29 花王株式会社 加熱瀝青質用添加剤
US4670575A (en) 1984-06-05 1987-06-02 Kao Corporation Process for purification of phosphoric mono esters
JPS61129189A (ja) 1984-11-28 1986-06-17 Kao Corp リン酸エステルまたはその塩の精製方法
US4736051A (en) 1985-03-20 1988-04-05 Kao Corporation Process for the preparation of an alkali metal salt of a diester phosphoric acid
US4751320A (en) 1985-11-27 1988-06-14 Kao Corporation Phosphoric ester and process for producing same
US5916884A (en) * 1985-12-04 1999-06-29 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing a mixture of phosphorus compounds and alkylglycerols
IE59778B1 (en) 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicament with anti-tumour action containing hexadecylphosphocholine
JPS62177008A (ja) 1986-01-29 1987-08-03 Kao Corp 共重合体の製造法
JPS63122775A (ja) 1986-11-12 1988-05-26 Kao Corp 油ゲル化剤
AU3757789A (en) 1988-05-18 1989-12-12 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates
JPH01290604A (ja) * 1988-05-18 1989-11-22 Dai Ichi Kogyo Seiyaku Co Ltd 水中崩壊性良好な農薬粒剤
US5059415A (en) 1989-02-21 1991-10-22 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health Method for diagnostically imaging lesions in the brain inside a blood-brain barrier
FR2677360B1 (fr) 1991-06-05 1995-04-14 Atta Composes amphiphiles perfluoroalkyles du phosphore, leurs preparations et leurs applications notamment dans le domaine biomedical.
US5846516A (en) 1992-06-03 1998-12-08 Alliance Pharmaceutial Corp. Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications
JP2710900B2 (ja) * 1992-09-02 1998-02-10 株式会社ディ・ディ・エス研究所 酸性官能基を有する脂質誘導体及び同誘導体によって被覆された微粒子キャリヤー
US5491004A (en) * 1994-05-26 1996-02-13 Henkel Corporation Process for applying a low soiling fiber finish
EP0765913B1 (en) * 1995-09-29 2002-08-28 Dainippon Ink And Chemicals, Inc. Process for the preparation of lactic acid-based polyester compositions
JP3747091B2 (ja) * 1996-03-22 2006-02-22 株式会社クラブコスメチックス アポトーシス誘導剤
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
WO1998055533A1 (en) * 1997-06-04 1998-12-10 Biocompatibles Limited Zwitterionic compounds and their use to cross-link collagenous materials
AU7781298A (en) * 1997-06-04 1998-12-21 Biocompatibles Limited Phosphate compounds
IL121269A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Compositions and methods for reversibly increasing permeability of biomembranes
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
JP2000053897A (ja) * 1998-08-07 2000-02-22 Kao Corp インクジェット記録用水系インク

Similar Documents

Publication Publication Date Title
CA2416808A1 (en) Derivatives of branched-chain lipophilic molecules and uses thereof
ES2285743T3 (es) Uso de un farmaco anticancerigeno no encapsulado para la preparacion de una formulacion para tratar neoplasias mediante inhlacion.
Vaage et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
Kumbham et al. Oleanolic acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma
US7311924B2 (en) Compositions and methods for treating cancer
ES2830447T3 (es) Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
EP0458894B1 (en) Lipid excipient for nasal delivery and topical application
Harrington et al. Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development
ES2500590T3 (es) Agente para aumentar el efecto antitumoral que comprende una preparación de liposoma de oxaliplatino y agente antitumoral que comprende la preparación de liposoma
CA2404737A1 (en) Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
PT1863448E (pt) Novas composições de lipossomas
BRPI0707059A2 (pt) método de formação de uma micela que compreende oxaliplatina, método de encapsulação de oxaliplatina em um lipossomo, micela, lipossomo, lipossomo que compreende uma quantidade eficaz de oxaliplatina, uso de um lipossomo, método de tratamento de cáncer e terapia de combinação
WO2008030818A2 (en) Novel liposome compositions
EP0496813A1 (en) LIPOSOME MICRORESERVOIR METHOD AND COMPOSITION.
US20210130487A1 (en) Cd20-targeted antibody coupling pharmaceutical preparation
JP5031162B2 (ja) ウイルス感染を二重ターゲティングおよびガン細胞をターゲティングするための組成物および方法
US20140256696A1 (en) Steroid conjugates
EP3102585A1 (en) Boronic acid esters and pharmaceutical formulations thereof
US20030170299A1 (en) Therapeutic methods for acute myeloid leukemia
CA2450087A1 (en) Benzisoselenazolonyl derivatives having antineoplastic, anti-inflammatory and antithrombotic activities as well as their use
Alexander et al. Improving nucleoside analogs via lipid conjugation: Is fatter any better?
HK1203188A1 (en) Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
NZ554765A (en) Pegylated Liposomal Doxorubicin In Combination With Ecteinescidin 743
TWI332007B (en) Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals
Swaminathan et al. Liposomes for pulmonary drug delivery